Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein - Wikidata - awgldk - TriplyDB

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

http://www.wikidata.org/entity/Q27667382

about

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches Quantification of HER family receptors in breast cancer Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.A single ligand is sufficient to activate EGFR dimers Activating HER2 mutations in HER2 gene amplification negative breast cancer Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.MuPIT interactive: webserver for mapping variant positions to annotated, interactive 3D structures.Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells Computational analyses of curcuminoid analogs against kinase domain of HER2 Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.Regulation of the catalytic activity of the EGF receptor.A structural perspective on the regulation of the epidermal growth factor receptor.A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.Combined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors.Structural Basis for the Non-catalytic Functions of Protein Kinases.Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.Statistical analysis of EGFR structures' performance in virtual screening.Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.Molecular basis for multimerization in the activation of the epidermal growth factor receptor Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of Syzygium alternifolium through molecular dynamics and pharmacophore-based screening.

P2860

Q21132316-F0327119-52B5-433F-BD30-B77A6FA5F02A Q26866534-66220201-D452-4BAE-A2C7-C179AF1A46EB Q27015506-A5514911-CCF7-4775-885F-8924966633FE Q27343048-1AF3955C-A043-45CD-BE01-DE87F429B922 Q27681167-AEC97BB3-F3AE-4507-84C4-99AF8759C057 Q27851987-B83B739C-E750-4C3C-98D2-9B26E6590FB1 Q28482282-16FD2EC5-CA7C-4928-AE1E-8546702F05C3 Q28547357-121821B2-DB19-433B-8CF9-FCE0770535F4 Q30368961-322ED338-675A-4551-8778-5368C95DDC4F Q30432282-309826F6-30EA-4B11-8B89-92BC829FA008 Q31036423-7950B278-A51C-46DD-AB3E-011DDC69DDAA Q33709820-DE9D8187-B066-43FC-8B48-A4F439586C1C Q34084939-4A06386F-83FF-4CB4-A993-385E441A364C Q34249179-88C49B4C-8BEC-4C5B-A565-FC8F772C182E Q35121287-12EF057F-420C-4196-88E7-6AEBE8691E68 Q35228445-DB6EEFB0-E7D8-4991-9E0D-EE3D7760CB8A Q35325158-A83F0637-8548-4274-B1D7-72EE1CD95432 Q35597077-853F8366-28F4-4A69-AF58-0E03FBAFEAEF Q35674768-85EC3CD7-8C29-4F9F-93EB-19D2C79F8590 Q35782291-D4C0A7D4-48E8-44F9-A1FC-5470BD7EB46B Q35786366-47B36A1E-7BF9-4EF9-8465-2A3C41C6B6EA Q35793876-EE48C93D-F2D1-4FEC-B68C-81BD89156B5B Q35820920-1E5208E2-1803-45A3-9056-309151497DE7 Q35879834-79FBB4D4-AD60-4188-B575-F1964740E6AC Q35896406-E6D94F31-84D6-42DE-9C82-14D3371E31C5 Q35937896-3D69ECF3-CBF8-48E5-A946-67179D9E3C2F Q36446161-C2DA78A2-00BB-4A34-85DE-A9437476AC75 Q36456386-70685FE7-DD6D-4192-95B1-5395D284F6C9 Q36511804-99D9D036-FF3F-44E2-843A-FC737FCF9D25 Q36568029-B857E72B-D078-4541-BAFC-C38B9C979733 Q36605624-59BB72D7-E73B-4A0F-AA9D-21F43195DD39 Q36785721-1F137B1C-0DF7-4FD8-917E-71FD25659165 Q36910173-943357C8-ADC3-4F53-A300-1098964748AA Q36993693-DA7EE15B-2DA4-4A0C-98EA-6117FB8CA81E Q37121766-D3E96D2B-5DA3-4FD1-989E-D8C568BEADC1 Q37132095-EE37598F-39DF-4DF6-9814-E954C977AADC Q37168481-E6801867-66AE-4C1D-A84B-CBD7B79E0E49 Q37234153-BB7382E9-B38E-450C-9536-C9E4CC18D026 Q37275761-4574A77A-6236-432E-9FAE-77B3693CF4FC Q37407445-6B1BA6DA-FE94-4B7D-8B75-6641209AF78C

P2860

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

http://www.wikidata.org/entity/Q27667382

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@ast

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@en

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@nl

type

label

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@ast

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@en

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@nl

prefLabel

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@ast

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@en

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@nl

P1433

Q27667382-06CDA0D8-D801-4F8C-A104-E0968AA5C18E

P1476

Q27667382-70CA867F-7C5E-4416-8FE8-13DFF7541735

P2093

Q27667382-1AEC9F6F-9410-4FD1-AD74-144E8A70B606

Q27667382-24FB771D-41BE-47D3-A223-A2D8EF61B45C

Q27667382-31C9860A-75F4-4A16-9520-7BD9DB585925

Q27667382-336ACBAD-E0CA-427E-96B4-8301218D1307

Q27667382-3F39B15C-5F4D-4BEA-893B-ECF59C2D2D6D

Q27667382-44B84DD0-BEC7-475A-93C8-88708CC090AA

Q27667382-5162F114-051D-4BF7-AD96-E2CDF6895E19

Q27667382-5F776002-3799-4309-9973-BA2269B7501E

Q27667382-827DC667-B3B5-4CC7-AF9E-DB2D82544B12

Q27667382-8A1D5F9E-8F87-4741-B69D-08F775EAA661

P2860

Q27667382-0BE1BD86-E2A8-4EC2-981E-817071C31A60

Q27667382-211BA20F-AF55-41EB-A901-A8DF63D41238

Q27667382-22D8B738-74B8-4290-9AE6-44040AAD69F4

Q27667382-23A7EF25-C316-43FD-86BA-E4C88AC48B92

Q27667382-282C11ED-78C6-441A-B556-AB0CE5FD7814

Q27667382-44027678-24D3-435F-AC3E-2FDFC6D23987

Q27667382-5443D93C-530A-40D9-824C-C8996120B00C

Q27667382-594FE9BC-FF4B-42B4-9F60-7984F0A316C7

Q27667382-5969D7EE-D382-4589-BFAB-9CC76BFB5F06

Q27667382-5BCE9C64-6A6D-47E0-9CD7-4181ED767D45

P304

Q27667382-127792F2-44DA-451E-A4C8-F1A6F07F80C2

P31

Q27667382-AC84CE9E-F9B1-4F6B-9F8E-9138F67FA465

P3181

Q27667382-0F4E50C2-C1B6-428E-8BDD-74556CFDE6A8

P356

Q27667382-38EDAEA6-BA89-44C6-84B5-D098CB512D2F

P407

Q27667382-3C229303-869E-4B33-A35A-4A28614680D2

P433

Q27667382-4B3A8FE5-315A-4C17-9AED-3943ADD93016

P478

Q27667382-12AAD338-F68D-4AF7-9C70-DA9CA64E708E

P577

Q27667382-1F0BE611-18AD-48A5-A217-D4F22BB650DC

P698

Q27667382-EEEE06CF-A3B8-4DAD-B565-7B02F11B8720

P921

Q27667382-7123CB99-EBDB-4086-9C9E-15BEF7268CEF

P932

Q27667382-DABA6D53-B459-486A-81DF-A2575257392E

P3181

P356

JBC.M110.206193

P1433

Journal of Biological Chemistry

P1476

Structural Analysis of the Mec ...... Kinase Domain of HER2 Protein

@en

P2093

Aki Hirokawa

http://www.w3.org/2001/XMLSchema#string

Andy Jennings

http://www.w3.org/2001/XMLSchema#string

Bi-Ching Sang

http://www.w3.org/2001/XMLSchema#string

Gyorgy Snell

http://www.w3.org/2001/XMLSchema#string

Hiroshi Miki

http://www.w3.org/2001/XMLSchema#string

Hua Zou

http://www.w3.org/2001/XMLSchema#string

Jason Yano

http://www.w3.org/2001/XMLSchema#string

Kathleen Aertgeerts

http://www.w3.org/2001/XMLSchema#string

Keiji Iwamoto

http://www.w3.org/2001/XMLSchema#string

Noriyuki Habuka

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

Mechanism of activation and inhibition of the HER4/ErbB4 kinase

Humanization of an anti-p185HER2 antibody for human cancer therapy

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

Untangling the ErbB signalling network

P304

18756-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

937004

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M110.206193

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21454582

http://www.w3.org/2001/XMLSchema#string

P921

P932

3099692

http://www.w3.org/2001/XMLSchema#string